Importantly, a proportion (<10%) of prostate carcinomas has low PSMA expression and ~30% of mCRPC patients do not respond to treatment with [177Lu]Lu-PSMA-617, when response is defined as any decrease in prostate-specific antigen (PSA) levels (13, 14). This evidence concerns the gene FOLH1 and prostate carcinoma.